NAS10029,430−1.28%S&P7,718−0.34%GOLD$4,038−0.34%BTC$80,235−1.27%VIX16.92+0.06%latest tape · as of 14:02 UTC
The Screen · Healthcare · Biotechnology
ANEBAnebulo Pharmaceuticals, Inc.
ANEB · PNK · USD · Market cap $13M · 2 employees
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the U…
FAIL · Does not pass the screen
0.28 USD
Price as of 26 Oct 2026Daily close, not a live quote
Screened 2026-10-26 · the tape above runs as of 14:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price0.28 USD at the 26 Oct 2026 close
Our ratingAvoid, current read markup
Ethical screenDoes not pass
Last reviewed26 Oct 2026 (3 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 0.28 against the desk's fair-value range, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price0.28 USD
Ethical score10.0/100
RatingAVOID
Our investment reviews on this name
2026-10-28Read Markup0.31-11.3% to today Distribution gives way to Markup first Markup read since October
2026-10-21Read Distribution0.31-11.3% to today ✓Markdown gives way to Distribution with volume flow in agreement
2026-10-11Read Markdown0.31-11.3% to today ✓Markup gives way to Markdown after a 17% slide in 14 weeks
2026-07-02Read Markup0.38-26.7% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Anebulo Pharmaceuticals, Inc. holds its Markup at $0.28. Consolidating, no directional conviction, held for 2 days.
As held on the ledger · 2026-10-26
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 2 days
Price at the screen
$0.28
Valuation
0.00 trailing · -0.80 forward price to earnings
Values screen
FAIL· score 10.0
Beta
-1.94
The Workings
Five Screens, Shown in Full
Does not pass. Cash ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.00%
Below 33%
Interest-bearing debt is just 0.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
42.63%
Below 33%
Interest-bearing cash and securities are 42.6% of assets, above the one-third limit.
Fail
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Anebulo Pharmaceuticals,'s business is fine, but its cash and interest-bearing securities are about 43% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ANEB's ethical verdict changes
Today ANEB does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads AVOID
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-26 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
At -0.8x forward earnings, the price already runs ahead of the business.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ANEB trades on PNK. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Markup · changed$0.31+0.0%Entry 11
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 64%. Our forward projection puts the odds of a 10% gain over the next month near 27%.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 64%. Our forward projection puts the odds of a 10% gain over the next month near 27%.
2026-10-11Markdown · changed$0.31+0.0%Entry 9
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 64%. Our forward projection puts the odds of a 10% gain over the next month near 27%.
2026-10-02Markup$0.31-17.3%Entry 8
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 17.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 64%. Our forward projection puts the odds of a 10% gain over the next month near 27%.
2026-09-21Markup$0.38+0.0%Entry 7
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 64%. Our forward projection puts the odds of a 10% gain over the next month near 27%.
2026-08-21Markup$0.38+0.0%Entry 6
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 64%. Our forward projection puts the odds of a 10% gain over the next month near 27%.
2026-07-21Markup$0.38+0.0%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 64%. Our forward projection puts the odds of a 10% gain over the next month near 27%.
2026-07-18Markup$0.38+0.0%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 64%. Our forward projection puts the odds of a 10% gain over the next month near 27%.
2026-07-17Markup$0.38+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 64%. Our forward projection puts the odds of a 10% gain over the next month near 27%.
2026-07-03Markup$0.38+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · ANEB
Date
Insider
Title
Type
Shares
Value
2024-12-23
ENGLISH ARON R
Director and Beneficial Owner of more than 10% of a Class of Security